Additionally, the European Society of Cardiology (ESC), in collaboration with other CVD prevention societies, put forth recommendations in 2016 that included the use of SGLT2 inhibitors in patients with diabetes and established CVD [82]. This evidence concerns the gene SLC5A2 and diabetes mellitus.